cyrilzakka/clinical-trials huggingface dataset:
Single Session Intervention for Building Self-Compassion Habits-RCT

The study will test a single session self-compassion intervention that leverages an ultra-brief contemplative exercise. It will evaluate the effect of this intervention on psychopathology, stress, growth mindset, positive affect, self-compassion and the automaticity of self-compassion, as well as the relationships between these constructs and the automaticity of self-compassion. The participants will be undergraduate students at a large public university.

The broad aims of the proposed research is to examine the outcomes of a single session psychological intervention and to further understand processes and factors associated with habit formation. undergraduate students at a large university will be randomly assigned to a self-compassion intervention (SCI), or an active control (AC), and complete assessments at baseline (pre-treatment) and 4 weeks later (post-treatment).

The investigators seek to examine the following: (A1) Determine whether the group who receives the SCI, relative to the AC, will experience increased self-compassion, growth mindset and positive affect, as well as reduced stress and psychopathology. (A2) Evaluate whether the SCI group shows greater increases in automaticity of self-compassion compared to the AC pre- to post-treatment. (A3) Assess whether greater pre- to post-treatment increases in automaticity of self-compassionate are associated with increased self-compassion, growth mindset, and positive affect, as well as reductions in stress and psychopathology.

The investigators hypothesize the following: (H1) SCI will promote greater increases in self-compassion, growth mindset, and positive affect, as well as greater reductions in stress and psychopathology from pre- to post-treatment, relative to AC. (H2) The SCI group will show greater increases in the automaticity of self-compassion than AC from pre- to post-treatment. (H3) Greater increases in the automaticity of self-compassion from pre- to post-treatment will be predicted by greater increases in self-compassion, growth mindset, and positive affect, as well as greater decreases in psychopathology and stress, from pre- to post treatment. To further understand the results obtained, the investigators will evaluate participants' frequency, adherence, and impressions of using the intervention.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older.
* English language proficiency.
* Able and willing to give informed consent.

Exclusion Criteria:

* Does not have email address or access to email.
* Not able/willing to participate in and/or complete the pre-treatment assessments
Awareness of Gynaecologists About Role of Physical Therapy in Genital Prolapse

The aim of this study will be to detect if there is awareness of gynecologists about the role of physical therapy in genital prolapse.

Physical therapy plays an important role in assessment, prevention and treatment of pelvic floor dysfunction and genital prolapse, it helps to stimulate and strength pelvic floor muscle.

Physical therapy treatments for the pelvic floor may include bladder training, pelvic floor muscles training with or without biofeedback, vaginal cones, electro stimulation or other adjuncts to training.


Eligibility Criteria:
Inclusion Criteria:

-

Gynaecologists in private and government hospitals in Egypt

Exclusion Criteria:

* Gynaecologists with less than 5years experience.
Comparison Between Right and Left Radial Approach in Patients Undergoing Percutaneous Coronary Procedures

Our aim is to compare between right and left radial approach in patients undergoing percutaneous coronary procedures regarding feasibility and complications.

The radial artery has progressively became the standard access site for percutaneous coronary procedures both diagnostic and interventional. The first trans-radial access for cardiovascular diagnostics dates to 1947.

In 1989, the first case series of 100 coronary angiographies performed through the radial access, demonstrating the safety and the fast mobilization of patients with the radial approach .

The main advantages of the radial approach are increased safety and comfort of the patients with reduction of bleeding complications and immediate post-procedure ambulation .with these advantages, current guidelines highly recommend radial access for coronary angiography and percutaneous coronary intervention.

Most clinical trials focused solely on the right radial approach and rarely consider the left radial approach. Indeed, the RRA has technical obstacles related to anatomy and clinical practice like increased incidence of tortuosity of the subclavian artery and radial-ulnar artery loop with the right radial approach.

Most operators use the right radial access as the left radial access increase operator discomfort during vascular access and procedure, especially in obese patients.

However, the left radial access has potential benefits for both the patient and operator. One of which is that the left radial approach is associated with lower fluoroscopy time compared with the right radial approach.

Left radial artery as well is an appropriate alternative access for coronary catheterization with less anatomical variations like tortuosity than the right radial artery Moreover, left radial access is preferred for right handed patients because of temporary post-procedural disability caused by hemostasis process in right radial artery access Also subclavian artery tortuosity is significantly more common on the right side and is an important cause of difficult, prolonged, or failed radial procedure.

Eligibility Criteria:
Inclusion Criteria:

* • All patients presented to assiut university cardiac catheterization laboratory and eligible for radial coronary procedures (either diagnostic or interventional )

Exclusion Criteria:

* • Patients with acute coronary syndrome.

  * Patients with chronic upper limb ischemia
  * Patients with AV fistula
  * Patients with severe renal impairment
  * Failure to successfully cannulate the radial artery
Comparison of Conventional With Sonography Assisted Breast Surgery After Neoadjuvant Chemotherapy

Aim of the study is to investigate whether intra-surgical visualisation of malignoma reduces the resection rate in the case of R1 resection compared to the procedure without sonographic visualisation


Eligibility Criteria:
Inclusion Criteria:

* 18 to 80 years
* Female
* Presurgical validated breast cancer
* Unifocal to multifocal findings
* Palpable and/o non-palpable findings
* Neoadjuvant chemotherapy
* Indication for breast conserving therapy
* General operation ability and anesthesia ability
* Consent to conventional breast conserving breast surgery with wire marking
* Ability and will to follow the study conditions
* Written declaration of consent after clarification

Exclusion Criteria:

* Sonographically not clearly delineate resection areal
* Exclusion criteria for breast conserving therapy
* Simultaneous participation in other interventional trials that interfere with this study at the investigator's discretion
TAP Block or Wound Infiltration for Laparoscopic Pediatric Appendectomy: a Pilot Study

Effectiveness of the TAP block compared to wound infiltration in controlling pain after laparoscopic appendectomy in children

Laparoscopic appendectomy is one of the main emergency surgical procedures performed in children.

The available local anesthesia techniques include wound infiltration or "wall" blocks such as the TAP (transversus abdominis plane) block.

The greater evidence on the adult population suggests that both techniques are valid for pain control in the immediate postoperative period, although wall blocks can guarantee a more prolonged analgesic effect over time.

The evidence on the pediatric population, on the other hand, is less strong and sometimes conflicting: therefore, the objective of our study is to verify the efficacy of TAP block compared to wound infiltration in the control of postoperative pain after appendectomy in pediatric patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged between 3 and 16 years, candidates for laparoscopic appendectomy for suspected acute appendicitis.
* ASA physical status Class I and II
* Informed consent signed by parents / legal guardians

Exclusion Criteria:

* severe obesity (BMI\> 95th percentile for age and weight)
* perforated appendicitis
* paralytic ileum
* non-stabilized neuropathies
* allergy to local anesthetics or analgesics used in the study protocol.
* patients on chronic opiate treatment
* need for perioperative hospitalization in intensive care with sedation and / or mechanical ventilation
Delayed Cord Clamping in Rhesus Disease of the Newborn

The objective of this clinical trial is to investigate the effects of delayed cord clamping on hyperbilirubinemia, the need for phototherapy, neonatal intensive care (NICU) admission

The study will include term or preterm infants born to Rh negative mother.

The enrolled infants will be randomized into two groups:

Group (1) will include infants with delayed cord clamping performed at 60 sec after birth Group (2) will include infants with early cord clamping within 15 seconds.

History and examination The data on the gender, gestational age, birth weight, length, head circumference, 5- minute Apgar scores, presence of jaundice requiring phototherapy or exchange transfusion, need for admission in neonatal intensive care unit, the presence of respiratory distress (RR \> 60 breath per minute) ,and length of hospitalization will be recorded.

The enrolled infants will be followed either with their mothers in the nursery or in NICU. Regarding the mothers; maternal age, maternal weight, any diseases, medication, and mode of delivery, and postpartum hemorrhage requiring blood transfusion will be recorded.

Eligibility Criteria:
Inclusion Criteria:

- term or preterm infants born to Rh negative mother

Exclusion Criteria:

* Infants with Rh negative factor
* major congenital malformation
* fetal hydrops
* short umbilical cord less than 25cm
* nuchal cord
* multiple gestation
* unstable maternal hemodynamic condition
* placenta abruption
* placenta previa
* uterine rupture
* denied to participate
* depressed neonates who will require immediate resuscitation
Effect of Bioptron Light Therapy on Dryness of Eyes in Postmenopausal Women

Dry eye disease (DED) is a growing public health concern affecting quality of life and visual function, with a significant socio-economic impact. It is more prevalent in the females and is being specifically in the menopausal and postmenopausal age group.

Bioptron light therapy is efficient in the elimination of allergic reactions, signs and symptoms of dry eye improving capillary circulation, immunity stimulation, relieving pain and establishing balance of tissue electromagnetic field

Around 60 postmenopausal women will be randomly divided into two equal groups, they all complain from dry eye symptoms, ranging from mild/normal to moderate and severe.

Group(A): will receive patient education program for four weeks. Group(B): will receive patient education program and bioptron light therapy for four weeks

Eligibility Criteria:
Inclusion Criteria:

* All participants are postmenopausal women.
* Their age above 50 years old
* All participants aren't on any systematic therapy.

Exclusion Criteria:

* • Injuries and previous surgical treatment of eyes

  * All patients with diagnosis of chronic blepharitis, meibominitis or any other eye infections
  * Participants with autoimmune diseases such as Sjögren's syndrome (SS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
  * Diabetic participants will be excluded.
  * Smokers will be excluded from the study.
  * The use of Hormone Replacement Therapy
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop


Eligibility Criteria:
Key Inclusion criteria

* Biopsy proven aggressive non-hodgkin's lymphoma

  * Follicular center lymphoma Grade 3.
  * Diffuse large B-cell lymphoma.
  * Mantle cell lymphoma.
  * Transformed lymphoma.
* Relapsed or refractory to previous therapy for lymphoma
* At least one prior combination chemotherapy regime
* Measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter
* Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2
* Willing to follow the pregnancy precautions

Key Exclusion criteria

* Any of the following laboratory abnormalities.

  * Absolute neutrophil count (ANC) \< 1,500 cells/mm\^3 (1.5\*10\^9/L).
  * Platelet count \< 60,000/mm\^3 (60\*10\^9/L).
  * Calculated creatinine clearance of \<50mL/min
  * Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) or Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times upper limit of normal (ULN).
  * Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)/conjugated bilirubin \>0.8mg/dL.
* Subjects who are candidates for and willing to undergo an autologous stem cell transplant.
* History of active Central Nervous System (CNS) lymphoma within the previous 6 months
* History of other malignancies within the past year
* Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C
Effectiveness of a Normalization of Eating Intervention Program for Treating Women With Eating Disorders

This study will evaluate the effectiveness of a new approach to a normalization of eating program, based on principles of cognitive-behavioral therapy, in treating women with anorexia nervosa or bulimia nervosa.

Eating disorders are real, treatable medical illnesses. They are often characterized by disturbances in eating behavior, such as drastic reduction of food intake or extreme overeating, as well as feelings of distress or extreme concern about body shape or weight. The two main types of eating disorders are anorexia nervosa and bulimia nervosa. A third type, binge-eating disorder, is pending approval as a formal psychiatric diagnosis. Eating disorders frequently develop during adolescence or early adulthood, and they occur more often in females than in males. Studies have shown cognitive behavioral therapy (CBT) to be the most effective approach to treating eating disorders. However, the applicability of these findings to clinical settings and intensive outpatient therapy programs (IOPs) remains unknown. This study will evaluate the effectiveness of a new approach to a normalization of eating (NOE) program, based on principles of CBT, in treating women with anorexia nervosa or bulimia nervosa.

Participants in this open-label study will be assigned to receive either treatment-as-usual (TAU) or NOE. Participants admitted to the study in the first 8 months of the trial will receive TAU. Those admitted after the first 8 months will take part in the NOE program. Participants may begin receiving treatment as soon as they enter the study and will continue receiving their assigned treatments for 6 weeks. All participants in the NOE group will be required to report to the study site three evenings a week. They will receive individual therapy, as well as take part in group and family therapy sessions. In addition, they will be supervised while eating a meal. Body weight, results of the Eating Disorders Examination and the Structured Clinical Interview for DSM-IV Axis I disorders, and self-report measures will be assessed post-treatment and at the Month 6 follow-up visit.

Note: Participants are recruited from the Renfrew Center's outpatient programs located in the Philadelphia area. Individuals outside of Renfrew cannot volunteer for this study. For more information about the Renfrew Center's inpatient or outpatient treatment programs, please call 1-800-RENFREW.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of an eating disorder or eating disorder not otherwise specified (except for binge eating disorder), as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association
* Agrees to remain in IOP treatment for at least 3 weeks
* Seeking treatment in one of the Renfrew Center's outpatient programs located in the Philadelphia area

Exclusion Criteria:

* Diagnosis of eating disorder not otherwise specified, including binge eating disorder
* Diagnosis of a psychotic disorder
* Transferred to inpatient treatment during the IOP stay because of worsening health
NLA101 in Adults Receiving High Dose Chemotherapy for AML

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.

Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with chemotherapy induced neutropenia (CIN) in adult subjects with AML.

Eligible subjects with untreated de novo or secondary AML and per local institutional standards planned to receive at least two cycles of chemotherapy with curative intent will be enrolled into the study and randomized 1:1:1:1 to 1 of 3 Investigational Arms (Standard of Care \[SOC\] chemotherapy + low, medium, or high dose NLA101) or a Control Arm (SOC chemotherapy).

Subjects randomized to an Investigational Arm will be eligible to receive a single fixed assigned dose of NLA101 after the first cycle of chemotherapy, and up to 2 additional identical cell doses after subsequent chemotherapy cycles (one NLA101 infusion per cycle). Subjects randomized to the Control Arm will be followed for up to 3 cycles of chemotherapy.

All subjects will be followed for 84 days following randomization, or 30 days post final infusion of NLA101, or 30 days post the day after the last chemotherapy infusion for Control Arm, whichever is longer.

Eligibility Criteria:
Key Criteria:

Inclusion Criteria:

* Age ≥ 18 (or legal age of majority for sites outside US).
* Untreated de novo or secondary acute myeloid leukemia (AML), including AML that has progressed from myelodysplastic syndrome (MDS), and histologically documented diagnosis
* Eligible for at least 2 cycles of standard of care AML chemotherapy that will result in moderate to severe myelosuppression and have curative intent
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 or Karnofsky Status of 50 to 100.
* Adequate cardiac, renal, and hepatic functions.

Exclusion Criteria:

* Extramedullary disease in the absence of bone marrow or blood involvement
* Acute promyelocytic leukemia (APL) with PML-RARA
* Prior AML therapy, with the exception of intrathecal chemotherapy or emergent radiation for myeloid sarcoma.
* Concurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or radiation
* Prior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplant
* Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)
* Active/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection
Study of Clinic-based vs. Self-use of a Misoprostol-only Regimen for Induced Abortion

The goal of the study is to determine whether important clinical outcomes differ among women who access a misoprostol-only medication abortion regimen from a patent medicine vendor when compared with those who access it from a clinic.

Medication abortion with a misoprostol-only regimen within the first 10 weeks of pregnancy is safe and effective. Investigators aim to assess whether self-use of early (\<9 weeks) medication abortion using a misoprostol-only regimen results in non-inferior rates of clinical outcomes when compared with clinic-based provision of medication abortion.

The investigators will prospectively recruit women who obtain misoprostol from patent medicine vendors and clinics. Follow-up will occur by telephone during three phone calls within 45 days of the first dose of misoprostol.

Eligibility Criteria:
Inclusion Criteria:

* Purchased a misoprostol-only abortion regimen at a PMV or from a clinic
* Be at least 15 years of age
* Have a known LMP of less than 9 weeks
* No contraindications to medical abortion
* Willing and able to give informed consent
* Have a mobile phone of which they are the independent user or be willing to be followed-up in person
* Willing to be contacted with questions about her abortion by telephone at 1-3, 10-29 and 30-45 days following initial contact.

Exclusion Criteria:

* Contraindications to misoprostol
* Age \<15 or \>49
Comparison of Outcome and Effectiveness Between Micropulse Diode Laser Cyclophotocoagulation and Cyclocryoablation in Treatment of Refractory Glaucoma

laucoma having bad prognosis after maximally tolerated medication,glaucoma that fails after filtering operations, neovascular glaucoma, glaucoma following vitrectomy and glaucoma secondary to uveitis etc. is collectively termed as refractory glaucoma. For such glaucoma patients, cyclodestructive procedures are often used to reduce IOP, as well as to relieve ocular and periocular pain. Recently,diode laser transscleral cyclophotocoagulation has proved to be an effective method for the treatment of refractory glaucoma and it has become a standard treatment for refractory glaucoma.(Yu, Q., Liang, Y., Ji, F. and Yuan, Z.,et al 2020. ) In previous articles, little is known about the long-term outcomes of micropulse diode laser cyclophotocoagulation and cyclocryotherapy. Discrepancies in the results of several large observational analyses have introduced further ambiguity on the role of micropulse diode laser cyclophotocoagulation and cyclocryotherapy.The mechanism of transcleral cyclophotocoagulation IOP lowering in refractory glaucoma is not well understood. In this study, we perform cyclocryoablation and micropulse diode laser cyclophotocoagulation in patients with refractory glaucoma and report the outcomes / mechanism of IOP control using this new surgical paradigm. The objective of our project is to assess the end result and outcome of the role of micropulse diode laser cyclophotocoagulation and cyclocryotherapy.We aim to evaluate the comparison between micropulse diode laser cyclophotocoagulation and cyclocryotherapy.

Only those subjects will be recruited who provide written informed consent. Patients are diagnosed on bases of tonometry, gonioscopy, ophthalmoscopy, perimetry. Patients' age, gender, type of glaucoma, number of diode laser treatment sessions, postoperative complications, number of hypotensive medications required to control IOP, and best corrected visual acuity (BCVA) will be evaluated. The criteria for success will be defined as postoperative IOP \<21 mmHg or \>20% decrease in IOP with or without additional medical treatment.


Eligibility Criteria:
Inclusion Criteria:

Positive diagnosis of refractory glaucoma

* Poor visual acuity: Hand movements or less
* Age ≥ 18 years
* Intraocular pressure ≥ 21 mmHg
* Signed informed consent

Exclusion Criteria:

* Eye surgery performed over the last 3 months
* Eye inflammation
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.


Eligibility Criteria:
Inclusion Criteria:

* Patients with Systemic Lupus Erythematosus (SLE)

Exclusion Criteria:

* Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE)
* History of chronic, recurrent, or recent severe infection
* Significant hematologic abnormalities
* History of cancer, heart failure, renal disease, liver disease or other serious illness